Transpek Q1 FY27: consolidated PAT falls 43% YoY to ₹8.93 Cr on margin compression
PAT -42.7% YoY · revenue -2.06% · margins compressing
₹151.06 Cr
-2.06% YoY
₹8.93 Cr
-42.7% YoY
5.76%
-3.6pp YoY
₹15.98
Transpek Industry's consolidated PAT fell 42.7% YoY to ₹8.93 Cr in Q1 FY27, even as revenue was nearly flat, down 2.1% YoY to ₹151.06 Cr — profit declined far faster than the topline. Standalone tells the same story (PAT ₹8.93 Cr, revenue ₹151.06 Cr), confirming the subsidiary adds negligible weight to either statement. Sequentially, both metrics look better — revenue up 1.9% and PAT up 35.7% over Q4 FY26 — but that quarter was itself a multi-quarter low (PAT ₹6.58 Cr, NPM 4.3%), so the QoQ bounce reads as a recovery off a weak base rather than a turnaround; the YoY comparison is the one that matters here.
Q1 FY-2027 vs prior quarters
The squeeze sits mainly on other income and operating costs rather than the topline. Other income collapsed 65.7% YoY, to ₹4.00 Cr from ₹11.66 Cr, and was the single largest swing factor behind the 43.7% YoY drop in PBT — total income fell 6.5% YoY even though revenue itself was down only 2.1%. On the cost side, total expenses eased just 1.2% YoY: net material cost (materials consumed less inventory drawdown) actually improved 5.3%, but that was offset by other expenses rising 13.2% YoY, holding total opex nearly flat against a shrinking topline. Consolidated OPM eased to about 13.3% from 15.6% a year ago (NPM to ~5.8% from ~9.4%), though both margins are up from Q4 FY26's 12.0%/4.3%.
The stock went into the print at ₹1,280, up 30.6% over the past month of trading.
What the summary numbers don't show
Basic EPS (consolidated) ₹15.98 vs ₹27.90 a year ago and ₹11.78 last quarter — standalone and consolidated figures are nearly identical.
Management gives no formal guidance on record, and no press release beyond the routine board-outcome letter to BSE accompanied this filing, so there is no company framing to reconcile against the print. No analyst previews or consensus estimates for this quarter were found in a web search — MarketsMojo's most recent public call was a 'Strong Sell' rating dated June 1, 2026, issued before this print and not tied to a specific PAT/revenue estimate, so vsStreet is unknown rather than inferred. Two shareholder-register changes (promoter Malti Bhatia reclassified to public, June 2, 2026) and a Senior GM (R&D & QC) resignation (July 13, 2026) fall in the quarter but are not numerically tied to the results. The company also filed an Expression of Interest for an Odisha investment (July 22, 2026), with no capex quantum disclosed yet — a marker to watch alongside whether the other-income line and margins normalize next quarter.
W1
Whether other income normalizes — it fell to ₹4.00 Cr this quarter from ₹11.66 Cr a year ago and was the largest single swing factor behind the YoY PBT decline.
W2
Progress on the Odisha investment EOI filed Jul 22, 2026 — watch for a formal announcement with a disclosed capex quantum.
W3
Margin trajectory — OPM at 13.3% this quarter is still below Q1 FY26's 15.6%; confirm whether the QoQ improvement from Q4 FY26's 12.0% continues into Q2 FY27.
Statement reported in ₹ Lakh, converted to Crore (cross-checked against prior-quarter context figures, exact match). No exceptional items in current or year-ago column. Standalone and consolidated are nearly identical — subsidiary Transpek Creative Chemistry Pvt Ltd is immaterial to the P&L.